Question IPR3100: May a patent owner challenge the standing of a petitioner in the preliminary response?
A patent holder may challenge the standing of a petitioner in the preliminary response. For example, a patent holder may provide evidence that the petitioner has filed a civil action challenging patentability prior to filing the petition or that the petitioner otherwise is estopped from challenging the patent owner’s claims.
Question IPR3020: Who may file for an inter partes review?
A person who is not the patent owner and has not previously filed a civil action challenging the validity of a claim of the patent may petition for an inter partes review of the patent.
mygn closing stock price now above closing price on 8/1/2014 (prior to run up before earnings call)............
Thomson Reuters/Verus upgrades MYRIAD GENETICS INC from HOLD to BUY.BY Investars Analyst Actions - public
— 11:05 AM ET 08/18/2014
On August 18, 2014 Thomson Reuters/Verus upgraded MYRIAD GENETICS INC (MYGN) from HOLD to BUY.
It is run on biopsy material.
"Prolaris is an absolute game changer for urologists because it adds meaningful new prognostic information in terms of risk assessment for prostate cancer patients that will improve their care," said E. David Crawford, M.D., head of the Section of Urologic Oncology at the University of Colorado. "In this study, Prolaris led to major changes in therapies with significant reductions or increases in interventional treatments that were based on patients' unique risk profiles."
new feature. you can search for providers by zipcode. i found three large urology practices near my zip who offer the test.
Prolaris was developed to help doctors predict prostate cancer aggressiveness, together with other clinical variables, such as : Gleason score and PSA. Technically, Prolaris measures how fast your tumor is growing.
The signature has been evaluated in four clinical studies:
•A study of 366 patients which predicted biochemical recurrence in patients who had undergone radical prostatectomy
•A study of 413 patients which predicted biochemical recurrence in patients who had undergone radical prostatectomy
•A study of 337 patients which predicted ten year mortality risk in patients with clinically localized prostate cancer diagnosed by transurethral resection and managed conservatively (watchful waiting)
•A study of 352 patients which predicted ten year mortality risk in patients with clinically localized prostate cancer diagnosed by needle biopsy and managed conservatively (watchful waiting)
Prolaris was a statistically significant predictor of clinical outcomes in all four studies. Prolaris provides unique additional information about your prognosis and may be used with other clinical factors to help your doctor recommend the treatment that you need.
Shares outstanding continue to shrink. Percent of shares outstanding that are short are going to increase if the outstanding shares drop 5% each year 2013, 2014, 2015 and beyond. could go above the current 50+ to even 55% to maybe 60%. the exit door keeps shrinking in size!! if someone yells fire, the stampede could be awesome!!
only need a catalyst like Prolaris coverage to start the stampede!!